All In Biotech

Investigational drug · Phase 2

TE-8105 MAD

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight and Obesity.

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

2

Any phase or sponsor naming "TE-8105 MAD"

First trial start

2024

Jul 9, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TE-8105 MAD", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Overweight and Obesity

Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "TE-8105 MAD" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Overweight and Obesity

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

  • MazdutideLY3305677Phase 35 trials

    Eli Lilly · Type 2 Diabetes, Obesity, Overweight

  • HDM1002Phase 34 trials

    Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight and Obesity

  • DA-302168SPhase 33 trials

    Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus

  • AZD9550Phase 23 trials

    AstraZeneca · Overweight and Obesity, Obesity/Overweight, Obesity or Overweight

  • CPX101Phase 21 trial

    Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. · Overweight and Obesity

  • WVE-007Phase 21 trial

    Wave Life Sciences USA, Inc. · Overweight and Obesity

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.